-+ 0.00%
-+ 0.00%
-+ 0.00%

Leadman (300289.SZ) subsidiary commences phase I clinical trial of recombinant group B meningococcal vaccine

Zhitongcaijing·11/17/2026 10:09:06
Listen to the news

Zhitong Finance App News, Leadman (300289.SZ) announced that the company recently learned that the recombinant B-group meningococcal vaccine (Escherichia coli) (“recombinant group B meningococcal vaccine”) independently developed by the holding subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (“Xiansheng Xiangrui”) has begun phase I clinical trials at the Hunan Provincial Center for Disease Prevention and Control.

A randomized, blinded, placebo-controlled phase I clinical trial of the recombinant group B meningococcal vaccine was initiated at the Hunan Provincial Center for Disease Prevention and Control to evaluate the safety, tolerability and initial immunogenicity of the vaccine in people aged 3 months and above.